Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) has received a consensus rating of “Moderate Buy” from the twenty-three research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the […]
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) Chairman Jeffrey M. Leiden sold 1,125 shares of the business’s stock in a transaction on Monday, May 8th. The shares were sold at an average price of $349.00, for a total transaction of $392,625.00. Following the completion of the sale, the chairman now owns 35,387 shares in the […]
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) Chairman Jeffrey M. Leiden sold 879 shares of the business’s stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $349.56, for a total transaction of $307,263.24. Following the completion of the sale, the chairman now owns 36,512 shares in the […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) had its price target raised by Oppenheimer from $350.00 to $410.00 in a research note released on Tuesday morning, The Fly reports. Several other brokerages also recently issued reports on VRTX. SVB Leerink reduced their price target on shares of Vertex Pharmaceuticals from $374.00 to $365.00 and set an […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) had its price objective raised by Stifel Nicolaus from $300.00 to $340.00 in a research report sent to investors on Tuesday morning, The Fly reports. Several other research firms also recently issued reports on VRTX. HC Wainwright lifted their price objective on Vertex Pharmaceuticals from $326.00 to $380.00 in […]